A Study to Evaluate Adverse Events, How the Drug is Tolerated, and How the Drug Moves Through the Body of Intravenous Infusions of ABBV-8736 in Adult Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 2, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Healthy Volunteer

Interventions

DRUG

ABBV-8736

Intravenous (IV) Infusion

DRUG

Placebo

IV Infusion

Trial Locations (1)

RECRUITING

Acpru /Id# 277377, Grayslake